These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15978302

  • 1. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 2. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K.
    Treat Respir Med; 2004 May; 3(3):173-81. PubMed ID: 15219176
    [Abstract] [Full Text] [Related]

  • 3. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 4. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 5. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 6. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T.
    Ann Allergy Asthma Immunol; 1999 Mar 22; 82(3):257-65. PubMed ID: 10094216
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T.
    Am J Respir Crit Care Med; 2002 Oct 15; 166(8):1084-91. PubMed ID: 12379552
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 15; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.
    Clin Ther; 2008 Aug 15; 30(8):1492-504. PubMed ID: 18803991
    [Abstract] [Full Text] [Related]

  • 10. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec 15; 16(92):257-8. PubMed ID: 18092426
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D.
    Lancet Respir Med; 2013 Mar 15; 1(1):51-60. PubMed ID: 24321804
    [Abstract] [Full Text] [Related]

  • 12. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar 15; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 13. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug 15; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

  • 14. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, VanderMeer A, Dorinsky P.
    Ann Allergy Asthma Immunol; 2004 Oct 15; 93(4):351-9. PubMed ID: 15521371
    [Abstract] [Full Text] [Related]

  • 15. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R.
    Respir Med; 2006 Jul 15; 100(7):1152-62. PubMed ID: 16675212
    [Abstract] [Full Text] [Related]

  • 16. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
    Galant SP, van Bavel J, Finn A, Gross G, Pleskow W, Brown A, Hamedani AG, Harding SM.
    Ann Allergy Asthma Immunol; 1999 Mar 15; 82(3):273-80. PubMed ID: 10094218
    [Abstract] [Full Text] [Related]

  • 17. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 18. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan 15; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 19. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 15; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 20. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul 15; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.